Ritesh Rathore, MD
Hematology & Oncology · Providence, RINPI 1467459263
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $124,566 of the $148,388 with a category attached, or 83.9%. E.r. Squibb & Sons, L.L.C. accounts for 70.9% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2021 at $40,472 and has fallen 93.4% since, to $2,683 in 2025. Among hematology & oncology clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 123 payments — averaging $1206.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$105K
- AstraZeneca$22K
- Sanofi$9K
- GSK$8K
- Deciphera Pharmaceuticals Inc.$2K
- Janssen Scientific Affairs, LLC$1K
- plus $938 from 10 others
Across 5 payments — averaging $16,341 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Trisalus Life Sciences, Inc.$50K
- Bristol Myers Squibb$31K
What the payments were for
- Consulting fees$15,58010%
- Speaking & faculty fees$124,56684%
- Travel & lodging$6,1584%
- Food & beverage$1,8001%
- Education$2840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 58 | $105,245 |
| AstraZeneca | 30 | $22,460 |
| Sanofi | 4 | $8,543 |
| GSK | 4 | $7,621 |
| Deciphera Pharmaceuticals Inc. | 6 | $2,411 |
| Janssen Scientific Affairs, LLC | 1 | $1,170 |
| Bristol Myers Squibb | 3 | $356 |
| Johnson & Johnson(2 entities) | 7 | $129 |
| Gilead | 1 | $120 |
| Sanofi-aventis U.S. LLC | 1 | $90 |
| Epizyme, Inc. | 1 | $65 |
| Exelixis Inc. | 2 | $63 |
| Merck | 2 | $59 |
| Astellas Pharma US Inc | 1 | $25 |
| Genentech USA, Inc. | 1 | $17 |
| Puma Biotechnology, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$148,388 in reported general payments places this provider in the 95th percentile of 68 hematology & oncology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 34 | $803,568 |
| BrukinsaZanubrutinib | 28 | $417,268 |
| JakafiRuxolitinib Phosphate | 17 | $313,245 |
| RevlimidLenalidomide | 13 | $271,704 |
| Abiraterone Acetate | 62 | $215,720 |
| ImbruvicaIbrutinib | 13 | $213,161 |
| Lenalidomide | 15 | $155,389 |
| MektoviBinimetinib | 12 | $69,111 |
| EliquisApixaban | 106 | $65,053 |
| Everolimus | 11 | $37,957 |
| CreonLipase/Protease/Amylase | 27 | $30,160 |
| Imatinib Mesylate | 30 | $14,396 |
| Exemestane | 12 | $2,221 |
| Megestrol Acetate | 16 | $1,974 |
| Prochlorperazine Maleate | 44 | $958 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $105,245 | $803,56834 claims |
| Bristol Myers SquibbRevlimid | $356 | $271,70413 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $1,170 | $215,72062 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 68 hematology & oncology providers in Rhode Island.
Other hematology & oncology in Providence
- William SikovProvidence$156K
- Anthony MegaProvidence$65K
- Adam OlszewskiProvidence$63K
- Hina KhanProvidence$34K
- Peter BarthProvidence$29K
- Thomas OllilaProvidence$19K
- John ReaganProvidence$18K
- Jennifer GassProvidence$16K
- Matthew HadfieldProvidence$10K
- Humera KhurshidProvidence$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.